HVTN 703/HPTN 081 (AMP)

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in sub-Saharan Africa

Sponsors:
Division of AIDS (DAIDS)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Protocol Summary:
AMP is a study testing an experimental antibody against HIV. AMP stands for Antibody Mediated Prevention. This is the idea of giving people antibodies that fight HIV to see if they will protect people from becoming HIV infected.

The AMP study tests an antibody called VRC01, a manufactured antibody against HIV. This is a new idea for HIV prevention that is related to what has been done in vaccine research. In traditional HIV vaccine studies, people get a vaccine and the researchers wait to see if their bodies will make antibodies against HIV in response to the vaccine. In this study, we skip that step and give people the antibodies directly.

Years: 2016 – present

Investigator: Nyaradzo Mgodi, MSc, MBChB, MMed (Protocol Co-Chair)

Locations: Spilhaus, Parirenyatwa, and Seke South CRSs

HPTN

Current Study

Comments are closed.

Website by Canton Becker